Sharing 'New Drug Development' Experience... '2022 International Clinical Trial Conference' Held on the 12th

National Clinical Trial Support Foundation, Ministry of Health and Welfare
Co-hosted with Ministry of Food and Drug Safety
'Next-Generation New Drug Development' Theme for 3 Days Starting from the 12th

[Asia Economy Reporter Kim Young-won] The Korea National Enterprise for Clinical Trials (KoNECT), in collaboration with the Ministry of Health and Welfare and the Ministry of Food and Drug Safety, will hold the '2022 KoNECT International Conference (KIC·KoNECT International Conference)'.

KoNECT announced on the 11th that the KIC will be held for three days starting from the 12th at the Conrad Hotel in Yeouido, Seoul.

Now in its 8th year, the 2022 KIC is themed "Next-Generation New Drug Development through Technological Innovation" and consists of a total of 18 sessions, including 7 keynote speeches and 8 special sessions. As a side event, a clinical trial job fair featuring 23 pharmaceutical and bio companies will be held, and solutions and services from 37 exhibiting companies (42 exhibition booths) will be introduced.

On the first day, the keynote speech followed by a talk show will share the development case of SK Biopharm's epilepsy treatment drug 'Xcopri' and various success factors and experiences in domestic new drug development.

The keynote speeches on the second day will introduce new initiatives and changes from domestic regulatory authorities such as the Ministry of Food and Drug Safety as well as regulatory authorities in the United States and Europe. On the final day, presentations will cover smart clinical trials, digital healthcare, and the current status of global new drug development mega-fund formation.

The 18 sessions, led by 115 session chairs, will be divided into 65 topics related to candidate substance discovery, clinical development, and commercialization. Topics include ▲clinical and approval strategies during the development stage ▲new drug development using Digital Therapeutics (DTx) and the metaverse ▲preparation for clinical trial approval by the US FDA and European EMA ▲considerations and success cases from investment attraction to IPO.

Additionally, for the first time at KIC, a 'job fair' for clinical trial industry stakeholders and job seekers from related domestic pharmaceutical universities will be held. Twenty-three companies will participate, with job talk shows and recruitment briefings taking place on the 12th and 13th. The job talk show on the first day will introduce various clinical trial roles from Medihelpline, CRScube, and Clips BNC, while the recruitment briefing on the 13th will have HR representatives from domestic and foreign CROs sharing their hiring plans.

In the 'Researcher-Sponsor Open Innovation' session, in collaboration with the Korean Association for Cancer Chemotherapy, a networking platform will be established connecting Jin Medicine, GI Innovation, Spark Biopharma, Cellabmed, and Abion’s cancer drug research with domestic young researchers. This will support the discovery of young researchers and the entry of candidate substances into clinical trials.

Byun Joon Bae, Chairman of KoNECT, stated, "The 2022 KIC is particularly meaningful as it has expanded the scope of clinical trials from the previous focus on clinical development to the entire cycle including candidate substance discovery, clinical development, and commercialization." He added, "Going forward, the foundation will also actively pursue various efforts such as training clinical experts and supporting recruitment."

Pre-registration for the conference is open until the 11th, and on-site registration is also available.

This content was produced with the assistance of AI translation services.